Oral Sortilin Inhibitor VES001 Safely Raises Progranulin in First Human Trial
A phase 1 randomized trial in 79 healthy adults demonstrates that the oral small-molecule sortilin inhibitor VES001 is well tolerated, ...
A phase 1 randomized trial in 79 healthy adults demonstrates that the oral small-molecule sortilin inhibitor VES001 is well tolerated, ...
Insilico Medicine plans to present first human Phase 1 data for the AI-designed pan-TEAD inhibitor ISM6331 in mesothelioma and other ...
A phase 1 trial found that intranasal creatine prodrug CBT101 was tolerated and produced exploratory EEG changes consistent with central ...
A Phase 1 trial found that an eight-week dosing interval produced stronger and longer-lasting antibody responses against H5N1 influenza than ...
A phase 1 trial found that the investigational BCMA-targeted CAR-T therapy anito-cel produced responses in all 38 participants with relapsed ...
In an exciting advancement toward refining treatments for breast cancer, a multinational team of researchers has unveiled groundbreaking results from ...
City of Hope, a distinguished leader in cancer and chronic disease research, has unveiled a series of pioneering studies and ...
In a groundbreaking advancement poised to reshape cancer therapy, researchers at the Calibr-Skaggs Institute for Innovative Medicines, part of the ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine